covid vaccine 457x220

Featured research: COVID-19 vaccine trial

Healthy adults aged 18-55 can now contribute to the world's search for an effective COVID-19 vacine by joining a trial of the candidate COVID-19 vaccine ChAdOx1 nCoV-19 at Southampton.

Please contact for more information.

Developed by clinical teams at the University of Oxford’s Jenner Institute and Oxford Vaccine Group, the vaccine is being tested for how strongy it stimulates the body's immune defences, protects against infection and its safety.

The study will involve up to 510 healthy volunteers between 18 and 55 with around 187 participants to be recruited at University Hospital Southampton.

ChAdOx1 nCoV-19 a is made from a weakened version of a common cold virus (adenovirus) from chimpanzees that has been genetically changed so that it is impossible for it to grow in humans. 

This has been combined with genes that make proteins from the COVID-19 virus (SARS-CoV-2) called spike glycoprotein which play an essential role in allowing the SARS-CoV-2 virus to attach to and enter the body's cells.

By vaccinating with ChAdOx1 nCoV-19, experts hope to turn the virus' spikes against it. By raising antibodies that stick to them it turns them into targets for the immune system to lock onto and destroy it, helping to stop the virus from entering human cells and therefore preventing infection. 

To find out more about the study and how to take part, contact